mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

Yin OQP et al. – Concurrent use of proton pump inhibitors (PPIs) or H2 blockers did not affect the pharmacokinetics and efficacy of nilotinib in patients with positive (Ph+) chronic myeloid leukemia in chronic phase (Ph+ CML–CP). [more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close